Related Experiment Video
Updated: Aug 22, 2026
Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles
Published on: January 4, 2012
Effective gene therapy for pancreatic cancer by cytokines mediated by restricted replication-competent adenovirus
1Department of Molecular Biotherapy Research, Cancer Institute, Tokyo, Japan.
Abstract:
Pancreatic cancer has a poor prognosis even when surgical treatment can be accomplished. Studies have demonstrated that pancreatic cancer is associated with various genetic abnormalities in oncogenes and tumor suppressor genes including p53. New therapeutic approaches for pancreatic cancer can be developed by targeting these genetic alterations. Adenovirus (Adv) lacking the 55-kDa E1B protein (E1B55K) replicates preferentially in p53-deficient cancer cells. We constructed E1B55K-deleted Adv (AxE1AdB), and studied its replication and cytopathic effect on pancreatic cancer cells. AxE1AdB replicated in and caused cell death of the p53-deficient pancreatic cancer cell lines tested (e.g., PANC-1, MIAPaCa-2, SU.86.86, BxPC-3, and PK-1). To enhance its therapeutic effect, we examined the combination of coinfecting this restricted replication-competent adenovirus (RRCA) with other Adv. Coinfection of E1-deficient Adv expressing the reporter lacZ gene (AxCAlacZ) together with AxE1AdB resulted in the replication of both viruses and a marked increase in reporter gene expression. PANC-1 cells coinfected with AxE1AdB and the Adv for human IL-2 (AxCAhIL2), produced 110 times more IL-2 than those infected with AxCAhIL2 alone. Similarly, coinfection of AxE1AdB and Adv for human IL-12 augmented the IL-12 production by 370-fold. Injecting AxE1AdB into the PANC-1 tumor of severe combined immunodeficient mice (SCID mice) resulted in marked reduction of the volume of the tumor. Moreover, injecting AxE1AdB with AxCAhIL2 into the PANC-1 tumor resulted in complete regression of the established tumors. These data suggest that RRCA, which augments the antitumor effect of a viral transgene (i.e., cytokines), may be a powerful tool for treating p53-deficient pancreatic cancer.
Insights
This study shows that a modified adenovirus that replicates in p53-deficient pancreatic cancer cells can effectively reduce tumor size and promote complete tumor regression when combined with cytokine-encoding adenoviruses, offering a new pancreatic cancer therapy.
Area of Science:
- Oncolytic virology
- Cancer genetics
- Gene therapy
Background:
- Pancreatic cancer has a poor prognosis, often linked to genetic abnormalities like p53 mutations.
- Targeting these genetic alterations presents opportunities for novel pancreatic cancer therapies.
Purpose of the Study:
- To investigate the therapeutic potential of E1B55K-deleted adenovirus (AxE1AdB) in p53-deficient pancreatic cancer.
- To evaluate the synergistic effects of combining AxE1AdB with other adenoviruses expressing therapeutic transgenes.
Main Methods:
- Constructed E1B55K-deleted adenovirus (AxE1AdB) for selective replication in p53-deficient cells.
- Assessed viral replication and cytopathic effects on pancreatic cancer cell lines.
- Examined combination therapy with adenoviruses expressing lacZ, IL-2, and IL-12.
- Evaluated in vivo efficacy in severe combined immunodeficient (SCID) mouse models with PANC-1 tumors.
Main Results:
- AxE1AdB replicated in and induced cell death in p53-deficient pancreatic cancer cell lines.
- Coinfection with AxE1AdB significantly enhanced reporter gene expression and cytokine production (IL-2, IL-12).
- In vivo studies showed AxE1AdB reduced tumor volume, and combination therapy with AxCAhIL2 led to complete tumor regression.
Conclusions:
- Restricted replication-competent adenovirus (RRCA) demonstrates potent antitumor activity against p53-deficient pancreatic cancer.
- RRCA can augment the therapeutic efficacy of viral transgenes, such as cytokines.
- This approach holds promise as a powerful tool for treating p53-deficient pancreatic cancer.
